menu search

RUBY / Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?

Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
Rubius Therapeutics (NASDAQ: RUBY ) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company. Instead, it looks like increasing interest from traders is behind today's gains as heavy trading takes place. Read More
Posted: Feb 14 2023, 09:19
Author Name: InvestorPlace
Views: 110596

RUBY News  

Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?

By InvestorPlace
February 14, 2023

Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?

Rubius Therapeutics (NASDAQ: RUBY ) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company. Instead, it looks l more_horizontal

Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?

By InvestorPlace
February 7, 2023

Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?

Rubius Therapeutics (NASDAQ: RUBY ) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. According to more_horizontal

Rubius: Poor Data, Punishing Environment, Beaten Stock

By Seeking Alpha
June 19, 2022

Rubius: Poor Data, Punishing Environment, Beaten Stock

Rubius presented unconvincing data at AACR. The stock is down 80% in just 3 months. more_horizontal

Here Are 3 Penny Stocks You Need to Know About in May 2022

By PennyStocks
April 25, 2022

Here Are 3 Penny Stocks You Need to Know About in May 2022

Which penny stocks are you watching in May? The post Here Are 3 Penny Stocks You Need to Know About in May 2022 appeared first on Penny Stocks to Buy, more_horizontal

Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

By Benzinga
April 8, 2022

Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in adv more_horizontal

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

By Zacks Investment Research
November 5, 2021

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

By Zacks Investment Research
November 5, 2021

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

By Zacks Investment Research
November 5, 2021

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal


Search within

Pages Search Results: